"Cancer drugs only started working once we realised that we actually had to measure what was going on in the tumour and match them appropriately [to patients]...we're just on the cusp of that approach being accepted in neuroscience."

Jenny Barnett is the CEO of Monument Therapeutics, a Biotech company using precision medicine approaches to develop new treatments for psychiatric and neurological conditions, and the Chief Scientific Officer of Five Lives, a digital therapeutics business focused on reducing dementia risk.

Jenny joined us on Careers in Discovery to discuss her career so far, why academia wasn't for her, how digital biomarkers can improve clinical trial performance and the things she had to learn to become an effective CEO.

Enjoy!